TY - JOUR
T1 - Lactobacilli Degrade Wheat Amylase Trypsin Inhibitors to Reduce Intestinal Dysfunction Induced by Immunogenic Wheat Proteins
AU - Caminero, Alberto
AU - McCarville, Justin L.
AU - Zevallos, Victor F.
AU - Pigrau, Marc
AU - Yu, Xuechen B.
AU - Jury, Jennifer
AU - Galipeau, Heather J.
AU - Clarizio, Alexandra V.
AU - Casqueiro, Javier
AU - Murray, Joseph A.
AU - Collins, Stephen M.
AU - Alaedini, Armin
AU - Bercik, Premysl
AU - Schuppan, Detlef
AU - Verdu, Elena F.
N1 - Funding Information:
Funding The work was supported by a Canadian Institutes of Health Research (CIHR) grant and a Boris Family award to EFV MOP# 142773. EFV holds a Canada Research Chair. DS is supported by research grants from the German Research Foundation DFG Schu 646/17-1 (ATI), and DFG Pic/Sch SPP 1656 (Intestinal microbiota), and from the Leibniz Foundation (SAW-2016-DFA-2). AC holds a Farncombe Family fellowship. JAM was supported by the Mayo Foundation, receives grant funding through the National Institutes of Health, Crohn Colitis America (CCA), DBV Technologies, Evelo, Vibrant Technologies, and Actobiotics and holds a patent US8617536, Prevotella histicola. PB and SMC are supported by CIHR Foundation grant #143253. PB holds Richard Hunt-AstraZeneca Chair in Gastroenterology. National Center for Advancing Translational Sciences, National Institutes of Health UL1 TR000040, supported AA and XBY. Funding The work was supported by a Canadian Institutes of Health Research (CIHR) grant and a Boris Family award to EFV MOP# 142773. EFV holds a Canada Research Chair. DS is supported by research grants from the German Research Foundation DFG Schu 646/17-1 (ATI), and DFG Pic/Sch SPP 1656 (Intestinal microbiota), and from the Leibniz Foundation ( SAW-2016-DFA-2). AC holds a Farncombe Family fellowship. JAM was supported by the Mayo Foundation, receives grant funding through the National Institutes of Health, Crohn Colitis America (CCA), DBV Technologies, Evelo, Vibrant Technologies, and Actobiotics and holds a patent US8617536, Prevotella histicola. PB and SMC are supported by CIHR Foundation grant #143253. PB holds Richard Hunt-AstraZeneca Chair in Gastroenterology. National Center for Advancing Translational Sciences, National Institutes of Health UL1 TR000040, supported AA and XBY. Author contributions: EFV and DS conceptualized and designed the study. AC and JLM performed animal, molecular, and microbiology experiments. DS and VFZ purified amylase trypsin inhibitor and analyzed amylase trypsin inhibitor degradation. XBY and AA analyzed antibodies. JAM sent nonobese diabetic-DQ8 mice. JJ performed Ussing Chamber experiments. JC provided bacterial strains. HJG and AVC performed histology and expertise in gluten-sensitized mice. MP, PB, and SMC analyzed motility and edited the manuscript. AC, JLM, EFV, and DS analyzed and interpreted data and wrote the manuscript. All authors discussed the results and edited the manuscript. Funding The work was supported by a Canadian Institutes of Health Research (CIHR) grant and a Boris Family award to EFV MOP# 142773. EFV holds a Canada Research Chair. DS is supported by research grants from the German Research Foundation DFG Schu 646/17-1 (ATI), and DFG Pic/Sch SPP 1656 (Intestinal microbiota), and from the Leibniz Foundation ( SAW-2016-DFA-2). AC holds a Farncombe Family fellowship. JAM was supported by the Mayo Foundation, receives grant funding through the National Institutes of Health, Crohn Colitis America (CCA), DBV Technologies, Evelo, Vibrant Technologies, and Actobiotics and holds a patent US8617536, Prevotella histicola. PB and SMC are supported by CIHR Foundation grant #143253. PB holds Richard Hunt-AstraZeneca Chair in Gastroenterology. National Center for Advancing Translational Sciences, National Institutes of Health UL1 TR000040, supported AA and XBY.
Publisher Copyright:
© 2019 AGA Institute
PY - 2019/6
Y1 - 2019/6
N2 - Background & Aims: Wheat-related disorders, a spectrum of conditions induced by the ingestion of gluten-containing cereals, have been increasing in prevalence. Patients with celiac disease have gluten-specific immune responses, but the contribution of non-gluten proteins to symptoms in patients with celiac disease or other wheat-related disorders is controversial. Methods: C57BL/6 (control), Myd88–/–, Ticam1–/–, and Il15–/– mice were placed on diets that lacked wheat or gluten, with or without wheat amylase trypsin inhibitors (ATIs), for 1 week. Small intestine tissues were collected and intestinal intraepithelial lymphocytes (IELs) were measured; we also investigated gut permeability and intestinal transit. Control mice fed ATIs for 1 week were gavaged daily with Lactobacillus strains that had high or low ATI-degrading capacity. Nonobese diabetic/DQ8 mice were sensitized to gluten and fed an ATI diet, a gluten-containing diet or a diet with ATIs and gluten for 2 weeks. Mice were also treated with Lactobacillus strains that had high or low ATI-degrading capacity. Intestinal tissues were collected and IELs, gene expression, gut permeability and intestinal microbiota profiles were measured. Results: In intestinal tissues from control mice, ATIs induced an innate immune response by activation of Toll-like receptor 4 signaling to MD2 and CD14, and caused barrier dysfunction in the absence of mucosal damage. Administration of ATIs to gluten-sensitized mice expressing HLA-DQ8 increased intestinal inflammation in response to gluten in the diet. We found ATIs to be degraded by Lactobacillus, which reduced the inflammatory effects of ATIs. Conclusions: ATIs mediate wheat-induced intestinal dysfunction in wild-type mice and exacerbate inflammation to gluten in susceptible mice. Microbiome-modulating strategies, such as administration of bacteria with ATI-degrading capacity, may be effective in patients with wheat-sensitive disorders.
AB - Background & Aims: Wheat-related disorders, a spectrum of conditions induced by the ingestion of gluten-containing cereals, have been increasing in prevalence. Patients with celiac disease have gluten-specific immune responses, but the contribution of non-gluten proteins to symptoms in patients with celiac disease or other wheat-related disorders is controversial. Methods: C57BL/6 (control), Myd88–/–, Ticam1–/–, and Il15–/– mice were placed on diets that lacked wheat or gluten, with or without wheat amylase trypsin inhibitors (ATIs), for 1 week. Small intestine tissues were collected and intestinal intraepithelial lymphocytes (IELs) were measured; we also investigated gut permeability and intestinal transit. Control mice fed ATIs for 1 week were gavaged daily with Lactobacillus strains that had high or low ATI-degrading capacity. Nonobese diabetic/DQ8 mice were sensitized to gluten and fed an ATI diet, a gluten-containing diet or a diet with ATIs and gluten for 2 weeks. Mice were also treated with Lactobacillus strains that had high or low ATI-degrading capacity. Intestinal tissues were collected and IELs, gene expression, gut permeability and intestinal microbiota profiles were measured. Results: In intestinal tissues from control mice, ATIs induced an innate immune response by activation of Toll-like receptor 4 signaling to MD2 and CD14, and caused barrier dysfunction in the absence of mucosal damage. Administration of ATIs to gluten-sensitized mice expressing HLA-DQ8 increased intestinal inflammation in response to gluten in the diet. We found ATIs to be degraded by Lactobacillus, which reduced the inflammatory effects of ATIs. Conclusions: ATIs mediate wheat-induced intestinal dysfunction in wild-type mice and exacerbate inflammation to gluten in susceptible mice. Microbiome-modulating strategies, such as administration of bacteria with ATI-degrading capacity, may be effective in patients with wheat-sensitive disorders.
KW - Bacterial Metabolism
KW - Food Allergy
KW - HLA
KW - Microbiome
UR - http://www.scopus.com/inward/record.url?scp=85065797254&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85065797254&partnerID=8YFLogxK
U2 - 10.1053/j.gastro.2019.02.028
DO - 10.1053/j.gastro.2019.02.028
M3 - Article
C2 - 30802444
AN - SCOPUS:85065797254
SN - 0016-5085
VL - 156
SP - 2266
EP - 2280
JO - Gastroenterology
JF - Gastroenterology
IS - 8
ER -